[CAS NO. 664334-36-5] Motixafortide (BL-8040)
Please click "REQUEST A QUOTE" button if you need other sizes or
custom synthesis
request a quote
If there is no stock, or you need other sizes or custom synthesis,
please:
PRODUCTS SPECIFICATIONS [664334-36-5]
Catalog
SLK-S9665
Brand
Selleck
CAS
664334-36-5
DESCRIPTION [664334-36-5]
Overview
| MDL | - |
|---|---|
| Molecular Weight | 2159.52 |
| Molecular Formula | C97H144FN33O19S2 |
| SMILES | - |
For research use only.
Storage
3 years,-20°C,powder
1 years,-80°C,in solvent
1 years,-80°C,in solvent
Shipping
Room temperature shipping(Stability testing shows this product can be shipped without any cooling measures.)
Preparing Stock Solutions
| 1 mg | 5 mg | 10 mg | |
| 1 mM | 0.4631 mL | 2.3153 mL | 4.6307 mL |
| 5 mM | 0.0926 mL | 0.4631 mL | 0.9261 mL |
| 10 mM | 0.0463 mL | 0.2315 mL | 0.4631 mL |
| 50 mM | - | - | - |
Description
Motixafortide (BL-8040, BKT140, TF 14016, 4-fluorobenzoyl, 4F-benzoyl-TN14003, T140) is an antagonist of with IC50 of ～1 nM. BL-8040 induces the of AML blasts by down-regulating , , and via altered miR-15a/16-1 expression.
In vitro
Treatment with BL-8040 induces the robust mobilization of AML blasts from the BM. In addition, AML cells exposed to BL-8040 undergoes differentiation. BL-8040 induces the apoptosis of AML cells in vitro. This apoptosis is mediated by the up-regulation of miR-15a/miR-16-1, resulting in down-regulation of the target genes BCL-2, MCL-1 and cyclin-D1. Overexpression of miR-15a/miR-16-1 directly induces leukemic cell death. BL-8040-induced apoptosis is also mediated by the inhibition of survival signals via the AKT/ERK pathways.
Powered by Arctom Copyright © 2025 Arctom.
All rights reserved.